Crossmark

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts

Crossref DOI link: https://doi.org/10.1007/s00262-026-04350-x

Published Online: 2026-03-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suzuki, Ryo

Watanabe, Satoshi https://orcid.org/0000-0003-0041-6981
Shono, Kunihiro

Masuda, Takaaki

Yanai, Kensuke

Yamazaki, Ryo

Ando, Yumi

Wakabayashi, Tomoya

Tanaka, Susumu

Sekiya, Tomoki

Kushiro, Kohei

Yanagimura, Naohiro

Sato, Miyuki

Tanaka, Tomohiro

Nozaki, Koichiro

Saida, Yu

Hokari, Satoshi

Arita, Masashi

Ohashi, Riuko

Shima, Kenjiro

Kimura, Yosuke

Aoki, Nobumasa

Ohshima, Yasuyoshi

Koya, Toshiyuki

Kikuchi, Toshiaki
License Information

Text and Data Mining valid from 2026-03-05

Version of Record valid from 2026-03-05
More Information

Article History

Received: 24 November 2025

Accepted: 23 February 2026

First Online: 5 March 2026

Declarations

:

: The authors declare no competing interests.

: All animal studies were approved by the Niigata University Institutional Animal Care and Use Committee.

Document is current

Any future updates will be listed below